54 active not recruiting. 54 Phase 3, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 54 | Active not recruiting 54 |
| Phase 2 | 7 | Active not recruiting 7 |
Follow Neuroectodermal Tumors: new trials by email Literature Review of Neuroectodermal Tumors trials Research Report on Neuroectodermal Tumors
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen Paltusotine, Placebo - Carcinoid Syndrome, Carcinoid | Phase 3 | Active not recruiting | Crinetics Pharmaceuticals Inc. | 141 | 2025-11-19 | 2026-10-15 |
| Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain Computed Tomography, Fractionated Stereotactic Radiation Therapy, Magnetic Resonance Imaging - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma | Phase 3 | Active not recruiting | NRG Oncology | 274 | 2024-12-12 | 2026-09-14 |
| A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma Niraparib, Temozolomide - Glioblastoma, GBM | Phase 3 | Active not recruiting | Ivy Brain Tumor Center | 450 | 2024-06-19 | 2026-07-01 |
| A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2) Naporafenib, Dacarbazine, Temozolomide - Advanced or Metastatic NRAS-mutant Melanoma | Phase 3 | Active not recruiting | Erasca, Inc. | 78 | 2024-04-29 | 2026-02-27 |
| Clinical Study of the Efficacy and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the Skin BCD-263, Opdivo - Advanced Melanoma, Melanoma (Skin) | Phase 3 | Active not recruiting | Biocad | 392 | 2024-03-21 | 2025-07-08 |
| A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma Bel-sar, Suprachoroidal Microinjector, Infrared Laser - Choroidal Melanoma, Indeterminate Lesions | Phase 3 | Active not recruiting | Aura Biosciences | 108 | 2023-12-06 | 2026-10-13 |
| A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma ABP 206, Nivolumab - Melanoma | Phase 3 | Active not recruiting | Amgen | 633 | 2023-11-02 | 2026-01-12 |
| IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma IDE196, Crizotinib, Pembrolizumab - Metastatic Uveal Melanoma | Phase 2 / Phase 3 | Active not recruiting | IDEAYA Biosciences | 420 | 2023-10-31 | 2026-02-17 |
| A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001) Intismeran autogene, Pembrolizumab, Placebo - Melanoma | Phase 3 | Active not recruiting | Merck Sharp & Dohme LLC | 1089 | 2023-07-19 | 2025-09-24 |
| A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma BCD-217, anti-PD1, Excision of the primary lesion - Melanoma Stage III, Melanoma (Skin) | Phase 3 | Active not recruiting | Biocad | 411 | 2023-04-05 | 2025-07-08 |
| A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma Nivolumab + Relatlimab, rHuPH20 - Melanoma | Phase 3 | Active not recruiting | Bristol-Myers Squibb | 579 | 2023-03-06 | 2026-08-26 |
| A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery Fianlimab, Cemiplimab, Pembrolizumab - Melanoma | Phase 3 | Active not recruiting | Regeneron Pharmaceuticals | 1564 | 2023-01-16 | 2026-07-06 |
| A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs Lutetium[177Lu] Oxodotreotide Injection, Octreotide LAR - Neuroendocrine Tumors | Phase 3 | Active not recruiting | Sinotau Pharmaceutical Group | 196 | 2022-08-31 | 2025-09-05 |
| A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma BCD-217, BCD-100, Placebo - Melanoma, Melanoma (Skin) | Phase 3 | Active not recruiting | Biocad | 270 | 2022-08-02 | 2025-02-27 |
| Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma Fianlimab, Cemiplimab, Pembrolizumab - Melanoma | Phase 3 | Active not recruiting | Regeneron Pharmaceuticals | 1546 | 2022-07-14 | 2026-04-22 |
| An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma Melphalan (3 mg/kg IBW) with Hepatic Delivery System (HDS) - Metastatic Ocular Melanoma, Metastatic Uveal Melanoma | Phase 3 | Active not recruiting | Delcath Systems Inc. | 30 | 2022-06-10 | 2023-12-21 |
| IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18) IO102-IO103, Pembrolizumab - Metastatic Melanoma, Unresectable Melanoma | Phase 3 | Active not recruiting | IO Biotech | 407 | 2022-05-17 | 2025-08-28 |
| Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation. Encorafenib and Binimetinib, Placebo to match Encorafenib ; Placebo to match Binimetinib - Melanoma | Phase 3 | Active not recruiting | Pierre Fabre Medicament | 815 | 2022-05-02 | 2023-11-22 |
| Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma Lomustine, Magnetic Resonance Imaging, Photon Beam Radiation Therapy - Glioblastoma, Gliosarcoma | Phase 3 | Active not recruiting | NRG Oncology | 265 | 2022-03-28 | 2026-08-17 |
| Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy RYZ101, Everolimus, Sunitinib - GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor | Phase 3 | Active not recruiting | RayzeBio, Inc. | 343 | 2022-03-24 | 2026-10-05 |
Showing 20 of 54. Sign in to see all of them.
Melanoma (28) · Glioblastoma (8) · Neuroendocrine Tumors (8) · Brain Neoplasms (5) · Astrocytoma (3) · Central Nervous System Neoplasms (3) · Glioma (3) · Oligodendroglioma (3) · Uveal Melanoma (3) · Adenoma, Islet Cell (2) · Carcinoid Tumor (2) · Carcinoma, Merkel Cell (2) · Carcinoma, Renal Cell (2) · Diabetes Mellitus, Insulin-Dependent, 12 (2) · Gastro-enteropancreatic neuroendocrine tumor (2)
Neoplasms by Histologic Type (54) · Neoplasms, Germ Cell and Embryonal (54) · Neoplasms, Nerve Tissue (54) · Neoplasms (53) · Neoplasms by Site (37) · Neuroendocrine Tumors (32) · Nevi and Melanomas (30) · Skin Diseases (28) · Skin and Connective Tissue Diseases (28) · Skin Neoplasms (26) · Neoplasms, Glandular and Epithelial (21) · Neoplasms, Neuroepithelial (14) · Glioma (10) · Astrocytoma (8)
Nivolumab (11) · Temozolomide (9) · pembrolizumab (9) · Ipilimumab (6) · Magnetic Resonance Spectroscopy (5) · CTLA-4 Antigen (4) · Specimen Handling (4) · Everolimus (3) · Interferon alpha-2 (3) · Introns (3) · Lomustine (3) · Octreotide (3) · Radiotherapy (3) · 177Lu-octreotide, DOTA(0)-Tyr(3)- (2) · Bevacizumab (2)
National Cancer Institute (NCI) (7) · Biocad (3) · Bristol-Myers Squibb (3) · Merck Sharp & Dohme LLC (3) · ITM Solucin GmbH (2) · NRG Oncology (2) · Regeneron Pharmaceuticals (2) · Alliance for Clinical Trials in Oncology (1) · Amgen (1) · Ascletis Pharmaceuticals Co., Ltd. (1) · Aura Biosciences (1) · Beijing Pearl Biotechnology Limited Liability Company (1) · Centre Oscar Lambret (1) · Children's Oncology Group (1) · Crinetics Pharmaceuticals Inc. (1)
United States (40) · France (29) · Italy (26) · Spain (26) · Canada (25) · Germany (25) · United Kingdom (24) · Australia (20) · Belgium (20) · Netherlands (18) · Poland (16) · Czechia (14) · Brazil (13) · Israel (13) · Switzerland (12)
Ahmad Tarhini (1) · Anna Nowak, MD (1) · Caroline Robert, MD (1) · Cezar A Iliescu, MD (1) · Christian Blank, Prof (1) · David Schiff, MD (1) · Dirk Schadendorf, Prof. Dr. (1) · Fabio M Iwamoto (1)
PMID 41811823, PMID 25649350, PMID 26615020, PMID 28384065, PMID 28801186, PMID 29393183, PMID 29528443, PMID 29658430, PMID 29784747, PMID 30480549, PMID 31386061, PMID 31395089, PMID 31870188, PMID 31895407, PMID 32946353, PMID 33152282, PMID 33422612, PMID 33857412, PMID 33857414, PMID 34000245, PMID 34292174, PMID 34655839, PMID 34986285, PMID 35220182, PMID 35272485, PMID 35275197, PMID 35367007, PMID 35659704, PMID 35969032, PMID 36029412, PMID 36166727, PMID 36265502, PMID 36416836, PMID 36628573, PMID 36648215, PMID 36748342, PMID 37104746, PMID 37131154, PMID 37167764, PMID 37272516, PMID 37665297, PMID 37845511, PMID 37870969, PMID 38319852, PMID 38320023, PMID 38452313, PMID 38485189, PMID 38753757, PMID 38828984, PMID 39146951
2023 (4), U10CA180820 (3), 2018 (2), 2019 (2), U10CA180821 (2), U10CA180868 (2), U10CA180888 (2), U24CA196172 (2), 2014 (1), P50CA108961 (1), P50CA121973 (1), U10CA021115 (1), U10CA031946 (1), U10CA032102 (1), U10CA098543 (1)